Olga Lerner
Endocrinology, Diabetes & Metabolism · Los Angeles, CANPI 1902093693
Payments from drug & device makers
Across 131 payments — averaging $20.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$416
- Novo Nordisk$356
- Boehringer Ingelheim$271
- AstraZeneca$236
- Mannkind Corporation$225
- Abbott$198
- plus $945 from 18 others
What the payments were for
- Food & beverage$2,54696%
- Education$412%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 20 | $416 |
| Novo Nordisk | 22 | $356 |
| Boehringer Ingelheim | 13 | $271 |
| AstraZeneca | 13 | $236 |
| Mannkind Corporation | 9 | $225 |
| Abbott | 7 | $198 |
| Lilly USA, LLC | 8 | $167 |
| Sanofi-aventis U.S. LLC | 8 | $139 |
| Medtronic(2 entities) | 6 | $127 |
| GSK | 5 | $97 |
| Dexcom, Inc. | 2 | $59 |
| Shire North American Group Inc | 2 | $47 |
| BETA Bionics, Inc. | 1 | $46 |
| Bayer | 2 | $34 |
| Insulet Corporation | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $33 |
| Zealand Pharma US, Inc. | 2 | $32 |
| Valeritas, Inc. | 2 | $24 |
| Corcept Therapeutics | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Tandem Diabetes Care, Inc. | 1 | $15 |
How this compares
$2,647 in reported general payments places this provider in the 55th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 118 | $102,908 |
| JardianceEmpagliflozin | 57 | $48,482 |
| MounjaroTirzepatide | 19 | $18,460 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 32 | $7,966 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $7,722 |
| Novolin NInsulin Nph Human Isophane | 28 | $2,680 |
| Novolin RInsulin Regular, Human | 25 | $1,522 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 15 | $974 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $728 |
| Bupropion Hcl SrBupropion Hcl | 12 | $254 |
| Levothyroxine Sodium | 24 | $214 |
| Methimazole | 31 | $192 |
| Glipizide | 16 | $76 |
| Metformin Hcl | 23 | $73 |
| Metformin Hcl ErMetformin Hcl | 13 | $57 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $356 | $102,908118 claims |
| Boehringer IngelheimJardiance | $271 | $48,48257 claims |
| Lilly USA, LLCMounjaro | $167 | $18,46019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Los Angeles
- Stanley HsiaLos Angeles$19.8M
- Shlomo MelmedLos Angeles$3.3M
- Sina TebiLos Angeles$2.4M
- Anthony HeaneyLos Angeles$788K
- Christian GastelumLos Angeles$421K
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.